TGF-β antisense-modified tumor cell vaccines for cancer

被引：0
|
作者：
Shawler, DL
Mantil, JC
Chu, L
Nicholson, GL
Murphy-Satter, C
Ruppert, JR
Kraus, GE
Fakhrai, H
机构：
[1] NovaRx Corp, San Diego, CA USA
[2] Wallace Kettering Neurosci Inst, Kettering, OH USA
来源：
MOLECULAR THERAPY | 2003年 / 7卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
1161
引用
收藏
页码：S447 / S448
页数：2
相关论文
共 50 条
  • [1] TGF-β antisense-modified tumor cell vaccines
    Fakhrai, H
    Mantil, J
    Liu, L
    Nicholson, G
    Satter, CM
    Ruppert, J
    Kraus, G
    Saadatmandi, N
    Shawler, DL
    CANCER GENE THERAPY, 2003, 10 : S37 - S37
  • [2] Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma
    Fakhrai, H.
    Mantil, J. C.
    Liu, L.
    Nicholson, G. L.
    Murphy-Satter, C. S.
    Ruppert, J.
    Shawler, D. L.
    CANCER GENE THERAPY, 2006, 13 (12) : 1052 - 1060
  • [3] Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma
    H Fakhrai
    J C Mantil
    L Liu
    G L Nicholson
    C S Murphy-Satter
    J Ruppert
    D L Shawler
    Cancer Gene Therapy, 2006, 13 : 1052 - 1060
  • [4] Phase II study of a TGF-β2 antisense gene modified allogeneic tumor cell vaccine (Lucanix) in advanced NSCLC.
    Nemunaitis, J. J.
    Dillman, R. O.
    Schwarzenberger, P.
    Senzer, N.
    Tong, A.
    Devol, E.
    Chamberlin, T.
    Shawler, D.
    Fakhrai, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 368S - 368S
  • [5] Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
    Olivares, Jairo
    Kumar, Padmasini
    Yu, Yang
    Maples, Phillip B.
    Senzer, Neil
    Bedell, Cynthia
    Barve, Minal
    Tong, Alex
    Pappen, Beena O.
    Kuhn, Joseph
    Magee, Mitchell
    Wallraven, Gladice
    Nemunaitis, John
    CLINICAL CANCER RESEARCH, 2011, 17 (01) : 183 - 192
  • [6] Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
    Nemunaitis, J.
    Senzer, N.
    Olivares, J.
    Kumar, P.
    Barve, M.
    Kuhn, J.
    Nemunaitis, T.
    Magee, M.
    Yu, Y.
    Wallraven, G.
    Pappen, B. O.
    Maples, P. B.
    GENE THERAPY, 2013, 20 (09) : 875 - 879
  • [7] Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
    J Nemunaitis
    N Senzer
    J Olivares
    P Kumar
    M Barve
    J Kuhn
    T Nemunaitis
    M Magee
    Y Yu
    G Wallraven
    B O Pappen
    P B Maples
    Gene Therapy, 2013, 20 : 875 - 879
  • [8] Phase II Study of Lucanix™ a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC)
    Nemunaitis, John
    Dillman, Robert O.
    Schwarzenberger, Paul O.
    Senzer, Neil
    Cunningham, Casey
    Cutler, Jodi
    Tong, Alex
    Kumar, Padmasini
    Pappen, Beena
    Hamilton, Cody
    DeVol, Edward
    Maples, Phillip B.
    Liu, Lily
    Chamberlin, Terry
    Shawler, Daniel L.
    Fakhrai, Habib
    MOLECULAR THERAPY, 2006, 13 : S424 - S425
  • [9] Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
    Schlingensiepen, KH
    Schlingensiepen, R
    Steinbrecher, A
    Hau, P
    Bogdahn, U
    Fischer-Blass, B
    Jachimczak, P
    CYTOKINE & GROWTH FACTOR REVIEWS, 2006, 17 (1-2) : 129 - 139
  • [10] Phase II Trial of Belagenpumatucel-L, a TGF-β2 Antisense Gene Modified Allogeneic Tumor Vaccine in Advanced Non Small Cell Lung Cancer (NSCLC) Patients
    Nemunaitis, John
    Nemunaitis, Michael
    Senzer, Neil
    Bedell, Cynthia
    Kumar, Padmasini
    Pappen, Beena
    Maples, Phillip B.
    Shawler, Daniel
    Fakhrai, Habib
    MOLECULAR THERAPY, 2009, 17 : S215 - S215
12345